Review



cross pathway validation with sar408701  (Sanofi)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Sanofi cross pathway validation with sar408701
    The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; <t>SAR408701:</t> Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.
    Cross Pathway Validation With Sar408701, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cross+pathway+validation+with+sar408701/med_rxiv__64898__2026__01__30__26345218-187-1-19?v=Sanofi
    Average 86 stars, based on 1 article reviews
    cross pathway validation with sar408701 - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results"

    Article Title: Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results

    Journal: medRxiv

    doi: 10.64898/2026.01.30.26345218

    The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.
    Figure Legend Snippet: The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.

    Techniques Used: Biomarker Discovery, Drug discovery, In Vitro, Cell Culture, In Vivo



    Similar Products

    cross pathway validation with sar408701  (Sanofi)
    86
    Sanofi cross pathway validation with sar408701
    The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; <t>SAR408701:</t> Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.
    Cross Pathway Validation With Sar408701, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cross+pathway+validation+with+sar408701/med_rxiv__64898__2026__01__30__26345218-187-1-19?v=Sanofi
    Average 86 stars, based on 1 article reviews
    cross pathway validation with sar408701 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.

    Journal: medRxiv

    Article Title: Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results

    doi: 10.64898/2026.01.30.26345218

    Figure Lengend Snippet: The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.

    Article Snippet: For cross-pathway validation with SAR408701 (tusamitamab ravtansine), we thankfully acknowledge the provision of data from the ADC development at Sanofi, which are not publicly available, though.

    Techniques: Biomarker Discovery, Drug discovery, In Vitro, Cell Culture, In Vivo